Cargando…

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afshar-Oromieh, Ali, Haberkorn, Uwe, Zechmann, Christian, Armor, Thomas, Mier, Walter, Spohn, Fabian, Debus, Nils, Holland-Letz, Tim, Babich, John, Kratochwil, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397661/ https://www.ncbi.nlm.nih.gov/pubmed/28280855 http://dx.doi.org/10.1007/s00259-017-3665-9

Ejemplares similares

Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
por: Zechmann, Christian M., et al.
Publicado: (2014)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
por: Giesel, F. L., et al.
Publicado: (2016)

Preliminary evaluation of prostate‐targeted radiotherapy using (131)I‐MIP‐1095 in combination with radiosensitising chemotherapeutic drugs
por: Tesson, Mathias, et al.
Publicado: (2016)

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2013)

Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2021)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
por: Sterzing, Florian, et al.
Publicado: (2015)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
por: dos Santos, José Carlos, et al.
Publicado: (2019)

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
por: Wüstemann, Till, et al.
Publicado: (2016)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy
por: Alberts, Ian, et al.
Publicado: (2022)

Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer
por: Birindelli, Gabriele, et al.
Publicado: (2021)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Feasibility and robustness of dynamic (18)F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation
por: Debus, Charlotte, et al.
Publicado: (2018)

Is nano too big?
por: Mier, Walter, et al.
Publicado: (2013)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
por: dos Santos, José Carlos, et al.
Publicado: (2022)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
por: Giesel, Frederik L., et al.
Publicado: (2015)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
por: Cardinale, Jens, et al.
Publicado: (2023)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Integration of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in prostate cancer patients
por: Will, Leon, et al.
Publicado: (2017)

Comparing the clinical performance and cost efficacy of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis
por: Alberts, Ian, et al.
Publicado: (2021)

Assessment of malignancy and PSMA expression of uncertain bone foci in [(18)F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies
por: Vollnberg, Bernd, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pfq91l2c8sq54ckbbecfn0dshq